Dexcom (DXCM) consistently outperformed market expectations by delivering impressive earnings results, beating numerous estimates. The consistently strong Continuous Glucose Monitoring (CGM) demand continues making Dexcom a robust growth stock. The company also recorded a narrower Q3 loss than expected and robust Q1 2024 performance. Dexcom's Stelo Glucose Biosensor received FDA approval, further boosting the prospects of the firm and the stock's value. Despite experiencing some losses, the firm's stock regularly recuperates due to strong financial performance. Dexcom also recently partnered with MD Revolution to boost diabetes management.
Dexcom DXCM News Analytics from Mon, 09 Oct 2023 07:00:00 GMT to Wed, 08 May 2024 12:00:25 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 2
